NUVB

NUVB

Nuvation Bio Inc

Rev โ€”top 1%5Y
Hold

Nuvation Bio Inc. develops biopharmaceuticals for cancer treatment, focusing on innovative therapies like IBTROZI, a ROS1 inhibitor for non-small cell lung cancer, and Safusidenib for high-risk IDH1-mutant astrocytoma in clinical trials.

โš•๏ธ Healthcare NYSE Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$725today

Score Overview

1 Year
Score
Net Growth26.78%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth170.10%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-72.52%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend60%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-259.65%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Nuvation Bio Inc fundamental performance

Across Nuvation Bio Inc's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 62M and net income went from -$ 41M to -$ 204M. Revenue increased in 50% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 6.42โ€”
1 Year2025-08-12
$ 2.32176.72%
5 Years2021-08-12
$ 8.86-27.54%
All Time2020-08-24
$ 10.00-35.80%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 169M-$ 149M$ 660M
2025$ 62M-$ 204M$ 529M
2024$ 7M-$ 567M$ 502M
2023$ 0.00-$ 75M$ 611M
2022$ 0.00-$ 104M$ 661M
2021$ 0.00-$ 86M$ 765M
IPO2020$ 0.00-$ 41M$ 215M

Explore beyond NUVB

You're looking at Nuvation Bio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies